spacer
home > ebr > spring 2007 > pushing biobank standardisation
PUBLICATIONS
European Biopharmaceutical Review

Pushing Biobank Standardisation

Establishing an effective biomedical tissue management system is an integral part of moves to standardise and harmonise biobanking practices, explains Dr Achim Quandt of QIAGEN GmbH

In cancer research, as with other areas of biomedical research, a major issue facing researchers is the great variation in the methods employed by different labs for collecting, storing and analysing biological samples. This affects the quality and comparability of research data, and can only be resolved by the widespread adoption of standardised and quality-controlled protocols. Such protocols in case-control, cohort and other epidemiological studies are required to facilitate the discovery and validation of relevant disease biomarkers and, ultimately, the development of diagnostics and therapeutics.

Initiatives at the national and international level to standardise and harmonise biobanking practices have already begun. In Europe, the European Commission and the Wellcome Trust organised a conference in 2005 to discuss the current state of biobanks in Europe and to propose future strategies, including greater harmonisation of programmes and standards and greater standardisation of protocols. Proposals will be submitted to the 7th Framework Programme for Research and Technological Development (FP7), an EU programme with a budget of over ˆ50 billion to fund trans-European research.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Achim Quandt joined QIAGEN GmbH, a leading supplier of sample and assay technologies, as Global Product Manager for gene expression analysis products in April 2000. His current role involves global responsibility for the biomedical research market segment, including biomedical tissue management and biobanking. Prior to this, he spent five years working in sales and marketing at molecular diagnostics companies. Achim has a PhD in Molecular Biology and has studied at Bielefeld University, Germany, and the University of Edinburgh, UK.
spacer
Dr Achim Quandt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement